<DOC>
	<DOCNO>NCT00004885</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether fluorouracil leucovorin plus irinotecan effective fluorouracil leucovorin alone colorectal cancer . PURPOSE : Randomized phase III trial compare effectiveness fluorouracil leucovorin without irinotecan treating patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Fluorouracil Leucovorin With Without Irinotecan Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy toxicity high-dose fluorouracil leucovorin calcium without irinotecan patient metastatic adenocarcinoma colon rectum . II . Compare progression-free survival , overall survival , response rate , duration response patient treat 2 regimen . III . Compare quality life patient treat 2 regimen . OUTLINE : This randomize , multicenter study . Patients randomize one two treatment arm . Arm I : Patients receive leucovorin calcium IV 2 hour follow fluorouracil IV 24 hour day 1 , 8 , 15 , 22 , 29 , 36 . Arm II : Patients receive irinotecan IV 30 minute follow leucovorin calcium IV 2 hour fluorouracil IV 24 hour day 1 , 8 , 15 , 22 , 29 , 36 . Treatment arm repeat every 7 week absence disease progression unacceptable toxicity . Patients arm I develop disease progression begin second-line therapy comprise irinotecan , fluorouracil , leucovorin calcium within 2 month progression . Patients complete response take study receive treatment one year . Quality life assess begin study , completion course , 4 week completion study , every 2 month disease progression death . Patients follow every 2 month disease progression death . PROJECTED ACCRUAL : A total 430 patient ( 215 per arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic adenocarcinoma colon rectum Measurable evaluable disease outside prior radiation port No CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) ( 1.5 time ULN liver metastasis present ) AST ALT great 3 time ULN ( 5 time ULN liver metastasis present ) Renal : Creatinine great 1.25 time ULN Cardiovascular : No severe cardiac disease No uncontrolled angina pectoris No myocardial infarction within past 6 month Gastrointestinal : No unresolved bowel obstruction subobstruction No uncontrolled Crohn 's disease ulcerative colitis No history chronic diarrhea Other : No second malignancy except carcinoma situ cervix nonmelanomatous skin cancer No uncontrolled severe medical condition Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy metastatic disease No prior adjuvant chemotherapy contain topoisomerase I inhibitors At least 6 month since prior adjuvant chemotherapy Endocrine therapy : Concurrent corticosteroid allow Radiotherapy : See Disease Characteristics Surgery : Not specify Other : At least 4 week since prior investigational drug No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>